Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Regulation of Transcription Factor YAP-TEAD by Non-coding RNA LINC00857 and the Inhibitory Effects on Ovarian Cancer Cell Proliferation

View through CrossRef
This study was aimed to explore the expression and mechanism of the transcription factor YAP-TEAD in the Hippo signaling pathway under the regulation of non-coding Ribonucleic Acid (RNA) LINC00857 in the proliferation of ovarian cancer cells, so as to provide a scientific research basis for clinical diagnosis and treatment of ovarian cancer. In the study, the ovarian cancer cell lines (BT 549) were rolled into a control group (normal culture-defined as BT549/NC) and a response group (transfected with non-coding RNA LINC00857 cultured cells-defined as BT 549YAP cells). The expression and proliferation ability of the transcription factor YAP-TEAD in the two groups of cancer cells were analyzed and compared. The results showed that the YAP-TEAD expression rate was the highest in Bt549 cells; the YAP content grade (0.18) in BT 549-YAP cells was lower than BT 549/NC (0.2) after transfection (P< 0.05); and the apoptotic rate of the response group (80%) was higher than that of the control group (25%) after the intervention. With the extension of culture time, the expression of CCN1 mRNA decreased (P< 0.05), and CCN2 mRNA increased (P< 0.05). After 12, 24, 36, and 48 hours, the apoptosis rate of the reaction group at different time points was higher than that of the control group (P< 0.01). When YAP-TEAD was down-regulated, the in vitro proliferation ability of BT 549- YAP cells was weakened compared with BT 549/NC and parental cells. It was concluded that the noncoding RNA LINC00857 can target the transcription factor YAP-TEAD in the Hippo signaling pathway to decrease its expression, thus inhibiting the proliferation, migration, and invasion of cancer cells, and promoting cell apoptosis.
Title: Regulation of Transcription Factor YAP-TEAD by Non-coding RNA LINC00857 and the Inhibitory Effects on Ovarian Cancer Cell Proliferation
Description:
This study was aimed to explore the expression and mechanism of the transcription factor YAP-TEAD in the Hippo signaling pathway under the regulation of non-coding Ribonucleic Acid (RNA) LINC00857 in the proliferation of ovarian cancer cells, so as to provide a scientific research basis for clinical diagnosis and treatment of ovarian cancer.
In the study, the ovarian cancer cell lines (BT 549) were rolled into a control group (normal culture-defined as BT549/NC) and a response group (transfected with non-coding RNA LINC00857 cultured cells-defined as BT 549YAP cells).
The expression and proliferation ability of the transcription factor YAP-TEAD in the two groups of cancer cells were analyzed and compared.
The results showed that the YAP-TEAD expression rate was the highest in Bt549 cells; the YAP content grade (0.
18) in BT 549-YAP cells was lower than BT 549/NC (0.
2) after transfection (P< 0.
05); and the apoptotic rate of the response group (80%) was higher than that of the control group (25%) after the intervention.
With the extension of culture time, the expression of CCN1 mRNA decreased (P< 0.
05), and CCN2 mRNA increased (P< 0.
05).
After 12, 24, 36, and 48 hours, the apoptosis rate of the reaction group at different time points was higher than that of the control group (P< 0.
01).
When YAP-TEAD was down-regulated, the in vitro proliferation ability of BT 549- YAP cells was weakened compared with BT 549/NC and parental cells.
It was concluded that the noncoding RNA LINC00857 can target the transcription factor YAP-TEAD in the Hippo signaling pathway to decrease its expression, thus inhibiting the proliferation, migration, and invasion of cancer cells, and promoting cell apoptosis.

Related Results

Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
Abstract 2200: A rational approach for discovery of inhibitors of YAP-TEAD interaction
Abstract The Hippo signalling pathway plays a major role in organ growth regulation and tumorigenesis. By sensing contact inhibition, the central kinase network of t...
Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders
Abstract LB029: Degraders of TEAD transcription factors based on interface 3 binders
Abstract TEAD transcription factors have emerged as clinically validated targets for Hippo-altered cancers, e.g. mesothelioma driven by NF2 inactivation/deficiency. ...
Abstract 1015: Head and neck cancer expression of YAP65: A novel oncogene
Abstract 1015: Head and neck cancer expression of YAP65: A novel oncogene
Abstract Yes-associated protein (YAP), a transcription coactivator associated with maintaining tissue size, is reported as an oncogene in many types of cancer includ...
Age dependent endothelial responses to pneumonia-induced Acute Lung Injury
Age dependent endothelial responses to pneumonia-induced Acute Lung Injury
Objective: Children with Pediatric Acute Respiratory Distress Syndrome (PARDS) have better outcomes than adults with ARDS. Animal studies suggest that the reasons for improved outc...
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
Rôle de la voie de signalisation Hippo dans le développement des ostéosarcomes
L'ostéosarcome (OS) est la tumeur osseuse primitive maligne la plus fréquente chez les enfants et les adolescents dont le pronostic reste mauvais, surtout lorsque des métastases so...
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
Abstract YAP activation in cancer is linked to poor outcomes, making it an attractive therapeutic target. Previous research focused on blocking the interaction of...
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers
ABSTRACT YAP activation in cancer is linked to poor outcomes, making it an attractive therapeutic target. Previous research focused on blocking the interaction of Y...

Back to Top